Len Schleifer (left) and George Yancopoulos, Regeneron (Vimeo)

Eyes on he­mo­phil­ia prize, Re­gen­eron adds a $100M wa­ger on joint de­vel­op­ment cam­paign with In­tel­lia

When George Yan­copou­los first signed up In­tel­lia to be its CRISPR/Cas9 part­ner on gene edit­ing projects 4 years ago, the up­start smart­ly ramped up its IPO at the same time. To­day, Re­gen­eron $REGN is com­ing back in, adding $100 mil­lion in an up­front fee and eq­ui­ty to sig­nif­i­cant­ly boot up a whole ros­ter of new de­vel­op­ment projects.

And they’re high­light­ing some clin­i­cal he­mo­phil­ia re­search plans in the process.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.